Login / Signup

Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al.

Hendrik Schulze-KoopsKlaus KruegerChristof Speckernull null
Published in: Annals of the rheumatic diseases (2020)
Keyphrases
  • sars cov
  • coronavirus disease
  • respiratory syndrome coronavirus
  • rheumatoid arthritis
  • healthcare
  • emergency department
  • adverse drug
  • skeletal muscle
  • drug induced